Loading...
Market
Will 23andMe's customer base grow by 20% or more by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
23andMe's public customer metrics or financial reports
Story
23andMe to Lay Off 200 Employees, Discontinue Therapeutics to Focus on Core Genetics Business
Nov 12, 2024, 12:41 AM
Genetic testing company 23andMe announced plans to lay off 40% of its workforce, or roughly 200 employees, incurring up to $12 million in one-time costs as part of a restructuring effort to streamline operations and reduce costs. The firm will discontinue its therapeutics division, effectively exiting the drug development business, to focus on its core consumer genetics offerings. The decision marks a significant shift for the company, which had previously embarked on drug discovery initiatives leveraging its vast genetic data.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Less than 300 • 25%
300 to 500 • 25%
501 to 700 • 25%
More than 700 • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
